RxDoctor Payments Data

James Clements, MD

Family Medicine · Glasgow, KYNPI 1417367376

Payments from drug & device makers

$8,550in general payments, 2019–2025

Across 632 payments — averaging $13.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Pfizer$675
  • Amgen$591
  • Novartis$591
  • Bayer$436
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$8,39098%
  • Education$1602%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,550 in reported general payments places this provider in the 90th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$274,308
Medicare patients
555
Services billed
13,929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide189$228,135
JardianceEmpagliflozin277$219,420
EliquisApixaban323$210,689
FarxigaDapagliflozin Propanediol238$204,186
JanuviaSitagliptin Phosphate134$148,509
MounjaroTirzepatide115$126,786
Trelegy ElliptaFluticasone/Umeclidin/Vilanter104$96,150
XareltoRivaroxaban100$81,920
TrulicityDulaglutide33$59,157
RybelsusSemaglutide25$53,569
LinzessLinaclotide63$47,832
VraylarCariprazine Hcl21$38,409
EntrestoSacubitril/Valsartan46$27,391
MyrbetriqMirabegron43$21,915
KerendiaFinerenone24$21,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,115$281,704214 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$363$254,688334 claims
AstraZenecaFarxiga, Brilinta, Breztri Aerosphere$293$221,944268 claims
PfizerEliquis, Premarin$675$217,037337 claims
Lilly USA, LLCMounjaro, Trulicity$300$185,943148 claims
MerckJanuvia, Belsomra$276$155,465147 claims
GSKTrelegy Ellipta, Anoro Ellipta$201$107,628120 claims
AbbVieLinzess, Vraylar$1,190$86,24284 claims
Johnson & JohnsonXarelto$75$81,920100 claims
NovartisEntresto$591$27,39146 claims
Astellas Pharma US IncMyrbetriq$392$21,91543 claims
BayerKerendia$436$21,69924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Glasgow

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →